- Home
- AMRN vs GOSS Comparison
AMRN vs GOSS Comparison
Compare AMRN & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- GOSS
- Stock Information
- Founded
- AMRN 1989
- GOSS 2015
- Country
- AMRN Ireland
- GOSS United States
- Employees
- AMRN N/A
- GOSS N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- GOSS Health Care
- Exchange
- AMRN Nasdaq
- GOSS Nasdaq
- Market Cap
- AMRN 236.4M
- GOSS 212.9M
- IPO Year
- AMRN 1993
- GOSS 2019
- Fundamental
- Price
- AMRN $0.50
- GOSS $0.74
- Analyst Decision
- AMRN Hold
- GOSS Strong Buy
- Analyst Count
- AMRN 2
- GOSS 5
- Target Price
- AMRN N/A
- GOSS $9.20
- AVG Volume (30 Days)
- AMRN 1.2M
- GOSS 881.6K
- Earning Date
- AMRN 10-30-2024
- GOSS 11-07-2024
- Dividend Yield
- AMRN N/A
- GOSS N/A
- EPS Growth
- AMRN N/A
- GOSS N/A
- EPS
- AMRN N/A
- GOSS N/A
- Revenue
- AMRN $241,021,000.00
- GOSS $105,322,000.00
- Revenue This Year
- AMRN N/A
- GOSS N/A
- Revenue Next Year
- AMRN N/A
- GOSS N/A
- P/E Ratio
- AMRN N/A
- GOSS N/A
- Revenue Growth
- AMRN N/A
- GOSS N/A
- 52 Week Low
- AMRN $0.50
- GOSS $0.50
- 52 Week High
- AMRN $1.37
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- AMRN 32.91
- GOSS 22.63
- Support Level
- AMRN $0.54
- GOSS $0.78
- Resistance Level
- AMRN $0.58
- GOSS $0.92
- Average True Range (ATR)
- AMRN 0.04
- GOSS 0.05
- MACD
- AMRN -0.01
- GOSS -0.01
- Stochastic Oscillator
- AMRN 2.97
- GOSS 0.00
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.